Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds See More Upside for Nevro Corp (NVRO) and WidePoint Corporation (WYY)

According to a recent 13G form filed with the Securities and Exchange Commission Kevin Kotler‘s (pictured) Broadfin Capital has added 1.18 million shares to its stake in Nevro Corp (NYSE:NVRO) taking the total amount to about 1.61 million shares, which amass about 5.76% of the company’s outstanding stock. In a separate Form 4 filing, Brett Hendrickson‘s Nokomis Capital disclosed surging its WidePoint Corporation (NYSEMKT:WYY) stake by over 4 million shares to 12.77 million shares held indirectly by the fund and representing about 17% of WidePoint’s outstanding shares.

Kevin Kotler

In the eyes of most traders, hedge funds are assumed to be underperforming, old investment tools of the past. While there are more than 8,000 funds in operation at present, hedge fund experts at Insider Monkey look at the aristocrats of this group, around 700 funds. Contrary to popular belief Insider Monkey’s research revealed that hedge funds underperformed in recent years because of their short positions as well as the huge fees that they charge. Hedge funds managed to outperform the market on the long side of their portfolio. In fact, the 15 most popular small-cap stocks among hedge funds returned 118% since the end of August 2012 and beat the S&P 500 Index by 60 percentage points (see more details here). This is a huge margin which is why hedge funds’ recent purchases are a strong indicator.

Brett Hendrickson
Brett Hendrickson
Nokomis Capital

Broadfin initiated a stake in Nevro Corp (NYSE:NVRO) during the second quarter with some 419,600 shares. Although the stock has traded nearly sideways since June, it is up by more than 31% so far this year. The $1.34 billion medical device company is focused on the treatment of neurological disorders and chronic pain. In its financial results for the second quarter Nevro reported a net loss per share of $0.77, which beat the estimates by $0.12 and revenue of $11.42 million was $1.72 million ahead of expectations. The company achieved a number of milestones during the quarter, including FDA approval for HF 10 Spinal Cord Simulation therapy, which is now being launched in the US. HF 10 therapy has benefited more than 4,000 chronic pain patients.

Follow Nevro Corp (NYSE:NVRO)
Trade (NYSE:NVRO) Now!

Among over 700 hedge funds that we track at Insider Monkey, the sentiment surrounding Nevro Corp (NYSE:NVRO) has been extremely bullish during the second quarter. The total number of funds holding the company in their portfolios increased to 19 at the end of June as compared to 13 a quarter earlier. The aggregate holdings during this period registered an increase to $225.98 million, representing 15.4% of the company’s market cap, from $88.09 million. Donald Chiboucis‘ Columbus Circle Investors increased its stake by 74% during the second trimester to 1.07 million shares valued at $57.26 million. On Columbus’ heels was Perceptive Advisors, managed by Joseph Edelman, which, after a 44% surge in its holding, disclosed ownership of 799,000 shares valued at $42.94 million. None of the company’s top ten stockholders within our database decreased their holdings during the quarter.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.